Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, gives an update on the progression-free survival (PFS) results of the GAIA/CLL13 trial (NCT02950051) which compares three time-limited venetoclax-based regimens: venetoclax plus rituximab (RV), venetoclax plus obinutuzumab (GV), or venetoclax plus obinutuzumab and ibrutinib (GIV) to chemoimmunotherapy in fit patients with previously untreated chronic lymphocytic leukemia (CLL). The trial showed that GV and GIV were superior to chemoimmunotherapy but there was no benefit in PFS for patients treated with RV. However, patients receiving GIV experienced higher rates of severe infections. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).